My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 313

    1.

    Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

    Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.

    Breast Cancer Res. 2007;9(1):R16.PMID: 17263897 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

    Fadare O, Wang SA, Hileeto D.

    Hum Pathol. 2008 Mar;39(3):331-6.PMID: 18261623 [PubMed - indexed for MEDLINE]Related articles

    3.

    Prognostic relevance of basal cytokeratin expression in operable breast cancer.

    Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R.

    Oncology. 2005;69(6):478-85. Epub 2006 Jan 12.PMID: 16410686 [PubMed - indexed for MEDLINE]Related articles

    4.

    Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.

    Liu ZB, Wu J, Ping B, Feng LQ, Di GH, Lu JS, Shen KW, Shen ZZ, Shaol ZM.

    Tumori. 2009 Jan-Feb;95(1):53-62.PMID: 19366057 [PubMed - indexed for MEDLINE]Related articles

    5.

    Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

    Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

    J Clin Pathol. 2009 Jul;62(7):624-8.PMID: 19561231 [PubMed - indexed for MEDLINE]Related articles

    6.

    Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

    Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ.

    Breast Cancer Res. 2007;9(5):R65.PMID: 17910759 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

    Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

    Mod Pathol. 2006 Feb;19(2):264-71.PMID: 16341146 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

    Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

    Clin Cancer Res. 2004 Aug 15;10(16):5367-74.PMID: 15328174 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

    Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

    Am J Surg Pathol. 2009 Jul;33(7):1093-7.PMID: 19390427 [PubMed - indexed for MEDLINE]Related articles

    10.

    Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

    Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD.

    BMC Cancer. 2007 Jul 24;7:134.PMID: 17650314 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

    Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.PMID: 18045647 [PubMed - indexed for MEDLINE]Related articles

    12.

    Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.

    Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J.

    Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91.PMID: 16857790 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.

    Laakso M, Loman N, Borg A, Isola J.

    Mod Pathol. 2005 Oct;18(10):1321-8.PMID: 15990899 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

    Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

    Breast Cancer Res. 2008;10(3):R53. Epub 2008 Jun 17.PMID: 18559090 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

    Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF.

    Clin Cancer Res. 2003 Jul;9(7):2406-15.PMID: 12855612 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

    Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

    Clin Cancer Res. 2008 Oct 15;14(20):6625-33.PMID: 18927304 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

    Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

    Hum Pathol. 2009 Nov;40(11):1528-33. Epub 2009 Aug 19.PMID: 19695680 [PubMed - indexed for MEDLINE]Related articles

    18.

    Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

    Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M.

    Clin Cancer Res. 2007 Apr 1;13(7):1987-94.PMID: 17404078 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

    JAMA. 2006 Jun 7;295(21):2492-502.PMID: 16757721 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

    Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O.

    Mol Oncol. 2009 Dec;3(5-6):469-82. Epub 2009 Aug 4.PMID: 19713161 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk